We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TENOFOVIR EMTRICITABINE SANDOZ (Sandoz Pty Ltd)
Product name
TENOFOVIR EMTRICITABINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 (255 working days)
Active ingredients
emtricitabine; tenofovir disoproxil succinate
Registration type
New generic medicine
Indication
Treatment of HIV-1 infection
TENOFOVIR, EMTRICITABINE SANDOZ (tablet) is indicated for the treatment of HIV infected adults over the age of 18 years, in combination with other antiretroviral agents.
Pre-Exposure Prophylaxis
TENOFOVIR, EMTRICITABINE SANDOZ is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples (see section 5.1 Pharmacodynamic properties, Clinical trials).
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine